Compare SKLZ & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKLZ | ACRV |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 47.6M |
| IPO Year | 2020 | 2022 |
| Metric | SKLZ | ACRV |
|---|---|---|
| Price | $2.87 | $1.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $14.00 | $13.00 |
| AVG Volume (30 Days) | 34.6K | ★ 864.7K |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.98 | 15.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $92,865,000.00 | N/A |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $12.68 | $691.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.10 | $1.05 |
| 52 Week High | $9.11 | $5.65 |
| Indicator | SKLZ | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 36.99 | 49.01 |
| Support Level | N/A | $1.49 |
| Resistance Level | $3.68 | $1.86 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 66.18 |
Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. The company's reportable business segments are: the Skillz segment and the Aarki segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is an artificial intelligence company that delivers advertising solutions. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube among others. The majority of its revenue is generated from the Skillz segment. Geographically, the company derives its key revenue from the United States and the rest from Israel, China, Malta, and other countries.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.